Aartik Sarma

Has grant

Assistant Professor

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Transcriptomic signatures of airway inflammation in acute respiratory diseases

Open Date: 2020-07-20

Close Date: 2020-12-31

Articles (6)

Year:

2026

Year:

2026

Background: Air pollution is a recognized risk factor for chronic cardiopulmonary disease, but its role in acute respiratory outcomes is unknown. Our objective was to determine the association between ambient air pollution exposure and clinical outcomes of acute respiratory failure. Methods: In this retrospective observational cohort study, data were extracted from ten geographically diverse U.S. health systems from 2018 through 2024. Participants included adult patients admitted to the intensive care unit (ICU) who met clinical criteria for acute respiratory failure within the first 24 hours of hospital admission. The primary study outcomes were in-hospital mortality and duration of invasive mechanical ventilation (IMV). We quantified each patient’s air pollution exposure using their residential county annual average of fine particulate matter (PM2.5) and nitrogen dioxide (NO2) preceding ICU admission. Findings: The study cohort included 166,152 patients (mean age, 61.7 years; 59% male) from 1,555 U.S. counties with wide exposure ranges. For every 10-ppb increase in NO2 exposure, the odds of in-hospital mortality were 9% higher (95% CI, 1.04–1.14). Each 10-µg/m3 increase in PM2.5 was associated with a 6% higher risk of death (95% CI, 1.04- 1.08). Each 10-ppb increase in cumulative NO2 exposure was associated with a 2% increase in duration of IMV (95% CI, 1%–3%; p=0.04), whereas PM2.5 exposure was not significantly associated with ventilation duration. In competing-risks analyses, each 10-ppb increase in NO2 exposure was associated with a 50% higher risk of death (SHR, 1.50; 95% CI, 1.16–1.94), relative to recovery. Interpretation: In this large, nationwide ICU cohort of patients with clinically defined ARF, higher cumulative exposure to ambient air pollution prior to admission was associated with increased adverse outcomes. These findings should inform air quality index thresholds and environmental policy.

Year:

2026

Research using lower respiratory tract (LRT) sampling may lead to improved understanding and management of patients with acute respiratory failure (ARF). Research bronchoscopy is a valuable tool for sampling the LRT during ARF. However, bronchoscopy may be limited by challenges with repeated sampling, the inability to sample the most severely ill patients, and increased resource utilization. “Noninvasive” sampling strategies, such as nonbronchoscopic bronchoalveolar lavage, endotracheal aspirate collection, and heat moisture exchange filter fluid collection, may expand the opportunity to collect LRT samples for research. Upper respiratory tract and sputum sampling may enable sampling in nonintubated patients with ARF, for whom there is no direct noninvasive access to the LRT. We convened a workshop with 32 experts from diverse continents, scientific backgrounds, and healthcare professions, all with experience in clinical or research practice during ARF. The Workshop goals were to review existing noninvasive sampling methods, evaluate their respective potential benefits and limitations, and identify future research priorities aimed at improving standardization and integration of these approaches into practice. Findings were generated by review of literature, expert presentations, meeting discussions, and electronic surveys using a modified Delphi approach. Participants agreed that each sampling method provides biologically meaningful data during ARF while also acknowledging that each method has benefits and limitations. Various potential advantages to noninvasive methods include reduced cost, enhanced speed, and ease of adoption compared with standard fiberoptic bronchoscopy. Despite the potential advantages, rigorous head-to-head comparisons between noninvasive methods and/or standard bronchoscopy are limited, which is a priority for future research. Additional research priorities include examination of the feasibility and benefit of serial sampling of the LRT and investigation of how LRT biomarkers are related to lung pathophysiology and patient-centered clinical outcomes during ARF. This Workshop Report provides guidance for investigators to integrate LRT sampling into their research and highlights key priorities, such as rigorous head-to-head comparison of sampling methods for research, to improve the standardization of noninvasive sampling methods and use of LRT sampling in research and clinical practice.

Year:

2025

Rationale Two molecular phenotypes of the acute respiratory distress syndrome (ARDS) with divergent clinical trajectories and responses to therapy have been identified. Classification as “hyperinflammatory” or “hypoinflammatory” depends on plasma biomarker profiling. Limited data are available about the differences in the pulmonary biology of the molecular phenotypes. Objectives To identify differences in the pulmonary biology of ARDS molecular phenotypes Methods We compared tracheal aspirate gene expression between hyperinflammatory and hypoinflammatory phenotypes in bulk RNA sequencing (RNASeq) from coronavirus disease (COVID-19) and non–COVID-19 ARDS and single-cell RNASeq from non–COVID-19 ARDS. In a subset of subjects, we also compared plasma proteomic data. Measurements and Main Results In bulk RNASeq analyses, 1,157 genes were differentially expressed (false discovery rate < 0.1) between phenotypes in non–COVID-19 ARDS, and 85 genes were differentially expressed between phenotypes in COVID-19 ARDS. Eighteen genes were reproducibly differentially expressed between phenotypes in both cohorts, including greater expression of IL32, HSPA8, and PPP3CC in hyperinflammatory ARDS. A total of 195 pathways were reproducibly enriched across the two cohorts by gene set enrichment analysis, including greater expression of granulopoiesis, T-cell and IFN signaling, and integrated stress response pathways in hyperinflammatory ARDS. Network analysis of single-cell RNASeq in a third group of patients identified greater T-cell signaling to other immune cells in hyperinflammatory ARDS. Conclusions Hyperinflammatory and hypoinflammatory ARDS molecular phenotypes have distinct respiratory biology. Hyperinflammatory ARDS is characterized by an increased IFN-stimulated gene expression and T-cell activation in the lungs.

Year:

2025

Dexamethasone is the standard of care for critically ill patients with COVID-19, but the mechanisms by which it decreases mortality and its immunological effects in this setting are not understood. Here we perform bulk and single-cell RNA sequencing of samples from the lower respiratory tract and blood, and assess plasma cytokine profiling to study the effects of dexamethasone on both systemic and pulmonary immune cell compartments. In blood samples, dexamethasone is associated with decreased expression of genes associated with T cell activation, including TNFSFR4 and IL21R . We also identify decreased expression of several immune pathways, including major histocompatibility complex-II signaling, selectin P ligand signaling, and T cell recruitment by intercellular adhesion molecule and integrin activation, suggesting these are potential mechanisms of the therapeutic benefit of steroids in COVID-19. We identify additional compartment- and cell- specific differences in the effect of dexamethasone that are reproducible in publicly available datasets, including steroid-resistant interferon pathway expression in the respiratory tract, which may be additional therapeutic targets. In summary, we demonstrate compartment-specific effects of dexamethasone in critically ill COVID-19 patients, providing mechanistic insights with potential therapeutic relevance. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.

Year:

2024

Collaborators (13)

Chad Hochberg

Assistant Professor of Medicine

Johns Hopkins University

UNITED STATES
View details

Luisa Morales-Nebreda

Northwestern University

UNITED STATES
View details

Peter Graffy

University of Chicago

UNITED STATES
View details

Christine Vigeland

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

William Bain

University of Pittsburgh

UNITED STATES
View details

Robert Hagan

Assistant Professor

University of North Carolina

UNITED STATES
View details

Alicia Rizzo

Assistant Professor

University of Pittsburgh Medical Center

UNITED STATES
View details

Charles Langelier

Associate Professor

UCSF Medical Center

UNITED STATES
View details

Angela Rogers

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Catherine A Gao

Northwestern Medicine

UNITED STATES
View details

Stephanie Christenson

Associate Professor in Residence

University of California, San Francisco

UNITED STATES
View details

Ravi Patel

Sr. Data Scientist in Immunology

University of California, San Francisco

UNITED STATES
View details

Daniel Horton

Professor

Northwestern University

UNITED STATES
View details